Multiple Sclerosis Mouse Models – Cuprizone-induced demyelination
mouse model
Test the efficacy of your remyelinating or neuroprotective compound, leveraging the gold standard cuprizone-induced demyelination mouse model of Multiple Sclerosis
Cuprizone-induced demyelination mouse model key characteristics
Cuprizone-induced demyelination mouse model is a gold standard mouse model for evaluating efficacy of novel therapeutics for multiple sclerosis focusing primarily oligodendrocyte precursor cells. Wild-type C57BL/6J mice fed a cuprizone-supplemented diet develop progressive demyelination of the corpus callosum and associated white and grey matter structures through selective oligodendrocyte apoptosis driven by copper chelation. Critically, since oligodendrocyte precursor cells are resistant to cuprizone toxicity, remyelination commences following cuprizone withdrawal, creating a defined, controllable window for evaluating remyelination-promoting therapies.
InnoSer performs preclinical efficacy studies in both acute (6-week) and chronic (12-week) cuprizone paradigms, each addressing distinct aspects of demyelination pathophysiology in diseases such as Multiple sclerosis and suited to different therapeutic hypotheses and dosing requirements. Importantly, the acute demyelination and remyelination model (6-week cuprizone diet followed by normal diet) captures oligodendrocyte loss, corpus callosum demyelination, and subsequent spontaneous OPC-driven remyelination within a relatively short disease and efficacy dosing window, enabling you to obtain quick insights into your compound’s efficacy. On the other hand, the chronic demyelination model (12-week cuprizone diet) enables longer dosing paradigms.
✓ InnoSer offers preclinical efficacy studies using the acute (6-week) and chronic (12-week) cuprizone paradigms
✓ Clemastine is available as positive control to benchmark the efficacy of your novel compounds
✓ Visually evoked potentials (VEP) available as a translationally relevant functional readout
✓ Histopathology (e.g., MBP, Caspr) used as endpoint structural readout to quantify degree of remyelination and paranodal junction integrity in the corpus callosum
As a preclinical immunology CRO, InnoSer offers well-established and clinically relevant multiple sclerosis mouse models, complemented with standardized study protocols to ensure consistency and reproducibility of your results. In addition, InnoSer offers preclinical research services using the lysolecithin-induced mouse model of multiple sclerosis and EAE mouse model. While both cuprizone-induced mouse model and lyolecithin mouse models enable you to test efficacy of compounds directed at remylienaiton, the EAE mouse model allows you to focus on the inflammatory component of Multiple sclerosis. However, as all models have their unique characteristics, we recommend discussing your study setup in close collaboration with our experts.
Align your dosing strategy with the biology
The cuprizone model offers flexible study designs spanning disease prevention, symptomatic intervention, and remyelination therapies. Depending on your therapeutic mechanism and development objectives, compound administration can be initiated at different stages of pathology progression.
InnoSer’s neuroscience team will help you match your compound’s mechanism to the right intervention window, model design, and endpoint panel — so your first in vivo study generates data that actually informs your next decision.
| Study type | Recommended dosing window | Typical applications |
|---|---|---|
| Preventive studies | Before cuprizone exposure or during the first week of cuprizone feeding. | Evaluate compounds targeting oligodendrocyte stress, apoptosis, metabolic dysfunction, or early neuroinflammatory processes before extensive demyelination develops. |
| Symptomatic studies | Weeks 2–6 of cuprizone exposure. | Assess therapeutic efficacy after pathology is established, including effects on neuroinflammation, demyelination, axonal damage, and disease progression. |
| Remyelination studies | Following cuprizone withdrawal (acute model) or during recovery from chronic cuprizone exposure. | Evaluate compounds that promote oligodendrocyte regeneration, remyelination, and functional recovery following established demyelinating lesions. |
Cuprizone-induced mouse model validation datasets
6週間のクプリゾン曝露期間終了時に、視覚誘発電位（VEP）の記録を用いて機能的脱髄を評価し、潜時（活動電位の伝導）と振幅（軸索損傷または持続的な脱髄を示す）の両方を評価した。
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway as a consequence of demyelination (**p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 10).
(B)VEPの振幅は、ベースラインと比較して6週目に高かったが、クプリゾン投与群と対照群の間では変化が見られず、軸索の喪失は認められなかった（Dunnettの多重比較検定を用いた二要因分散分析；N = 10）。データは平均 ± 標準偏差で示されている。
Functional demyelination was assessed at the end of the 12-week cuprizone exposure period using visual evoked potentials (VEPs), evaluating both latency (conduction of action potentials) and amplitude (axonal integrity).
(A) VEP latency was significantly prolonged in cuprizone-treated mice compared with untreated controls, indicating impaired signal conduction through the visual pathway (****p < 0.0001 vs. baseline; Two-way ANOVA with Dunnett’s multiple comparisons test; N = 5-32).
(B) VEP amplitude remained comparable between cuprizone-treated and control animals, demonstrating no axonal loss (Two-way ANOVA with Dunnett’s multiple comparisons test; N = 6-8). Data are represented as mean ± SD.
Key readouts in the Cuprizone mouse model:
あなたの研究を支える人々
ソフィー・カーマンス博士
主任神経科学研究員
当社の神経学モデルにおいて豊富な経験を持つ専門家チームを率い、適切なモデルの選択を支援し お客様の研究を導きます 最適な 研究設計を. 当社は 解決策を accele評価
ハッセルト大学／バイオメッド
多発性硬化症（MS）の非臨床研究を推進するための共同イニシアチブの一環として、InnoSerはBIOMEDの研究者らと協力しており、同研究者らは 多発性硬化症（MS）における免疫学的メカニズム、髄鞘形成、および脳内の病変進行過程に焦点を当てています。
よくあるご質問
What reference compounds can InnoSer work with in the cuprizone mouse model?
For preclinical efficacy studies in the cuprizone mouse model, InnoSer recommends selecting Clemastine as the reference benchmark for your new compound. Clemastine fumarate is a well-established, approved antihistamine drug. Its mechanism of action is antagonism of the M1 muscarinic acetylcholine receptor (M1R) on oligodendrocyte precursor cells (OPCs), which removes a negative regulatory signal for OPC differentiation into mature myelinating oligodendrocytes.
Furthermore, across the scientific literature, Clemastine fumarate has a well-characterised dose-response relationship in the cuprizone model, enhancing remyelination (Li et al., 2015), and has been tested in clinical trials in Multiple Sclerosis patients (Green et al., 2017). This provides you with a direct, translational benchmark that helps link your efficacy datasets to the published clinical literature.
How does the cuprizone mouse model differ from EAE mouse model of multiple sclerosis that InnoSer works with?
The key distinction between the cuprizone-induced mouse model and the EAE mouse model lies in the immune mechanism driving demyelination.
The cuprizone model induces oligodendrocyte apoptosis through metabolic toxicity, with demyelination occurring in the absence of significant peripheral adaptive immune infiltration, in contrast to the EAE model, T and B lymphocytes do not play a central role in the development of demyelinating pathology. Therefore, the cuprizone-induced mouse model is more suitable for compounds targeting oligodendrocyte biology, oligodendrocyte precursor cell (OPC) differentiation and repair pathways, without the confounding influence of immune‑mediated processes.
In the EAE mouse model, by contrast, the disease pathology of multiple sclerosis, is driven by T and B cell-mediated neuroinflammation. Therefore, for compounds primarily targeting peripheral T cell or B cell-mediated immunity, the EAE model is more appropriate.
Contact our team to discuss which model best fits your compound’s mechanism of action.
What is the value of adding VEP as a readout in my preclinical efficacy study in the cuprizone model?
Visually evoked potentials (VEPs) measure the brain’s electrical response to visual stimuli, providing a direct functional assessment of myelin integrity along the visual pathway. In clinical practice, this method is used to assess the functional integrity of the visual pathways, particularly in the context of demyelinating disease, such as Multiple sclerosis.
In preclinical mouse models, functional assessment using VEPs offers a sensitive and translational measure of myelin integrity; demyelination slows the conduction of action potentials, which is reflected as a prolongation of VEP latency, while a reduction in amplitude may indicate axonal injury or persistent demyelination (Leocani et al., 2018). In accordance, subsequent remyelination restores the signal conduction velocity.
VEPs therefore serve as a functional biomarker of myelin repair and complement structural readouts such as myelin basic protein (MBP) or the paranode marker Contactin-Associated Protein (Caspr) quantification and histological analysis (Caverzasi et al., 2023; Green et al., 2017). Together, the cuprizone model and VEP readout constitute a powerful experimental framework for evaluating the remyelinating efficacy of pharmacological agents.
Discover Other Relevant Mouse Models
InnoSerの最新研究を発見する
Plasma NfL, p-tau217, or Aβ42/40: Which Alzheimer’s disease biomarkers should you include in your preclinical efficacy study?
A practical guide to preclinical Alzheimer’s disease biomarkers panel selection when you’re considering outsourcing to a specialist neurology CRO Biomarkers have transformed Alzheimer's disease clinical trials, enabling diagnosis confirmation for trial eligibility,...
Transgenic Amyloid, Tau, Seeding, or combined Amyloid/Tau pathology mouse models — which is the right one for your drug development program?
A practical guide to model selection when outsourcing your Alzheimer's disease efficacy study to a specialist neurology CRO Choosing the right Alzheimer's disease mouse model is one of the most consequential early decisions in a preclinical drug development program....
Morris Water Maze, Rotarod and beyond: How do you build a comprehensive behavioral test battery when outsourcing your preclinical Alzheimer’s disease efficacy study?
A practical introduction to behavioural test battery selection when outsourcing your Alzheimer's disease efficacy study to a specialist neurology CRO When outsourcing a preclinical Alzheimer's disease efficacy study, behavioral endpoint selection is one of the most...
STXBP1 Foundation and InnoSer validate R122X, a patient-variant mouse model of STXBP1 encephalopathy, to help expand therapeutic opportunities in STXBP1 research
Gene therapies, antisense oligonucleotides (ASOs), RNA editing technologies, and other precision medicine approaches are rapidly transforming the therapeutic landscape for STXBP1 encephalopathy. Currently, around 16 candidate therapies are in development across five...
AAALAC認定
InnoSerはAAALAC認証を取得し、責任ある動物ケアと利用への取り組みを実証しています。AAALAC Internationalは、自主的な認証および評価プログラムを通じて科学における動物の適切な扱いを推進する非営利組織です。InnoSerのオランダおよびベルギー施設は、それぞれ2016年および2020年よりAAALAC認証を取得しています。AAALAC認証プログラムの詳細はこちらをご覧ください。
動物福祉
3R原則は、政策や規制の変更から新技術・手法の開発と普及に至るまで、あらゆる分野に影響を及ぼします。このためInnoSerは、これらのプロセスに対する継続的な取り組みと監視を実施しています。当社が実践する手順は、動物実験の代替・削減・改善を最大限に実現し、研究および医薬品開発におけるこれらの原則への取り組みを促進します。
info@innoserlaboratories.com